8
May
2025

NewLimit’s Anti-Aging Bounty, a Twist Spinout, & AI Coming to the FDA

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.

You may also like

Vigil, Inozyme Acquired, Prime Cuts, & Regeneron Scoops Up 23andMe
Genentech’s Bet on NC, GSK Buys Boston Liver Drug, & Septerna Entices Novo
FDA in Crisis, Parker Institute Snags Big Fish, & Merida Megaround
FDA Gutted, Novartis Kidney Drug Pays Off, and Isomorphic Raises a Fortune